{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:20:19Z","timestamp":1788254419925,"version":"build-2803163510"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11060-026-05738-6","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:17:10Z","timestamp":1785842230000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Brain metastases in triple-negative breast cancer: a systematic review of current trends, treatment strategies, and outcomes"],"prefix":"10.1007","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3988-8911","authenticated-orcid":false,"given":"Emir","family":"Begagi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6904-2490","authenticated-orcid":false,"given":"Hakija","family":"Be\u010duli\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amila Kov\u010di\u0107","family":"Har\u010dinovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nejla","family":"Huseinspahi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4134-987X","authenticated-orcid":false,"given":"Emir","family":"Be\u0107irovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Tluli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kre\u0161imir","family":"Tomi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9743-7265","authenticated-orcid":false,"given":"Semir","family":"Vrani\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"5738_CR1","unstructured":"Board WHOCoTE. Breast Tumours. 5th edition ed. Vol. 2, Lyon (2019) France: International Agency for Research on Cancer; (WHO Classification of Tumours)"},{"key":"5738_CR2","doi-asserted-by":"crossref","unstructured":"Smolarz B, Nowak AZ, Romanowicz H (2022) Breast Cancer-Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). Cancers (Basel).;14(10)","DOI":"10.3390\/cancers14102569"},{"key":"5738_CR3","doi-asserted-by":"crossref","unstructured":"Gupta I, Sareyeldin RM, Al-Hashimi I et al (2019) Triple Negative Breast Cancer Profile, from Gene to microRNA, in Relation to Ethnicity. Cancers (Basel).;11(3)","DOI":"10.3390\/cancers11030363"},{"key":"5738_CR4","doi-asserted-by":"publisher","first-page":"576964","DOI":"10.3389\/fpubh.2020.576964","volume":"8","author":"O Prakash","year":"2020","unstructured":"Prakash O, Hossain F, Danos D et al (2020) Racial Disparities in Triple Negative Breast Cancer: A Review of the Role of Biologic and Non-biologic Factors. Front Public Health 8:576964","journal-title":"Front Public Health"},{"issue":"2","key":"5738_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10549-016-4059-6","volume":"161","author":"X Li","year":"2017","unstructured":"Li X, Yang J, Peng L et al (2017) Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat 161(2):279\u2013287","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"5738_CR6","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1002\/cncr.32771","volume":"126","author":"SM Hercules","year":"2020","unstructured":"Hercules SM, Hercules JC, Ansari A et al (2020) High triple-negative breast cancer prevalence and aggressive prognostic factors in Barbadian women with breast cancer. Cancer 126(10):2217\u20132224","journal-title":"Cancer"},{"issue":"8","key":"5738_CR7","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.humpath.2009.01.003","volume":"40","author":"DJ Williams","year":"2009","unstructured":"Williams DJ, Cohen C, To TV et al (2009) Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray. Hum Pathol 40(8):1176\u20131181","journal-title":"Hum Pathol"},{"key":"5738_CR8","doi-asserted-by":"crossref","unstructured":"Bray F, Laversanne M, Sung H et al (2024 May-Jun) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","DOI":"10.3322\/caac.21834"},{"key":"5738_CR9","doi-asserted-by":"crossref","unstructured":"Berger ER, Park T, Saridakis A et al (2021) Immunotherapy Treatment for Triple Negative Breast Cancer. Pharmaceuticals (Basel).;14(8)","DOI":"10.3390\/ph14080763"},{"issue":"10","key":"5738_CR10","doi-asserted-by":"publisher","first-page":"e230034","DOI":"10.1148\/rg.230034","volume":"43","author":"BE Adrada","year":"2023","unstructured":"Adrada BE, Moseley TW, Kapoor MM et al (2023) Triple-Negative Breast Cancer: Histopathologic Features, Genomics, and Treatment. Radiographics 43(10):e230034","journal-title":"Radiographics"},{"issue":"3","key":"5738_CR11","doi-asserted-by":"publisher","first-page":"502","DOI":"10.17305\/bjbms.2022.8163","volume":"23","author":"Q Guo","year":"2023","unstructured":"Guo Q, Lan T, Lu Y et al (2023) Effectiveness of adjuvant chemotherapy for elderly patients with triple-negative breast cancer. Biomol Biomed 23(3):502\u2013509","journal-title":"Biomol Biomed"},{"issue":"7","key":"5738_CR12","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.17305\/bb.2024.11865","volume":"25","author":"MZ Kocak","year":"2025","unstructured":"Kocak MZ, Araz M, Findik S et al (2025) A preliminary study on the prognostic significance of cysteine-rich EGF ligand domain 2 protein (CRELD2) in patients with triple negative breast cancer. Biomol Biomed 25(7):1663\u20131671","journal-title":"Biomol Biomed"},{"issue":"8","key":"5738_CR13","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.clbc.2023.07.008","volume":"23","author":"R Bansal","year":"2023","unstructured":"Bansal R, Van Swearingen AED, Anders CK (2023) Triple Negative Breast Cancer and Brain Metastases. Clin Breast Cancer 23(8):825\u2013831","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"5738_CR14","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/neuonc\/noaa285","volume":"23","author":"M Kuksis","year":"2021","unstructured":"Kuksis M, Gao Y, Tran W et al (2021) The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis. Neuro Oncol 23(6):894\u2013904","journal-title":"Neuro Oncol"},{"issue":"8","key":"5738_CR15","doi-asserted-by":"publisher","first-page":"e2225424","DOI":"10.1001\/jamanetworkopen.2022.25424","volume":"5","author":"XY Wang","year":"2022","unstructured":"Wang XY, Rosen MN, Chehade R et al (2022) Analysis of Rates of Brain Metastases and Association With Breast Cancer Subtypes in Ontario, Canada. JAMA Netw Open 5(8):e2225424","journal-title":"JAMA Netw Open"},{"key":"5738_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejca.2016.12.015","volume":"74","author":"JP Leone","year":"2017","unstructured":"Leone JP, Leone J, Zwenger AO et al (2017) Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis. Eur J Cancer 74:17\u201325","journal-title":"Eur J Cancer"},{"issue":"1","key":"5738_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s11060-024-04651-0","volume":"168","author":"E Mashiach","year":"2024","unstructured":"Mashiach E, Alzate JD, De Nigris Vasconcellos F et al (2024) Improved outcomes for triple negative breast cancer brain metastases patients after stereotactic radiosurgery and new systemic approaches. J Neurooncol 168(1):99\u2013109","journal-title":"J Neurooncol"},{"issue":"1","key":"5738_CR18","doi-asserted-by":"publisher","first-page":"6707","DOI":"10.1038\/s41467-024-50558-9","volume":"15","author":"HU Balinda","year":"2024","unstructured":"Balinda HU, Kelly WJ, Kaklamani VG et al (2024) Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial. Nat Commun 15(1):6707","journal-title":"Nat Commun"},{"issue":"23","key":"5738_CR19","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.22.00520","volume":"40","author":"N Ramakrishna","year":"2022","unstructured":"Ramakrishna N, Anders CK, Lin NU et al (2022) Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update. J Clin Oncol 40(23):2636\u20132655","journal-title":"J Clin Oncol"},{"key":"5738_CR20","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"issue":"10","key":"5738_CR21","first-page":"Ed000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ et al (2019) Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 10(10):Ed000142","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"5738_CR22","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1136\/emermed-2020-209567","volume":"37","author":"M Amir-Behghadami","year":"2020","unstructured":"Amir-Behghadami M, Janati A, Population (2020) Intervention, Comparison, Outcomes and Study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews. Emerg Med J 37(6):387","journal-title":"Emerg Med J"},{"issue":"1","key":"5738_CR23","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/PRS.0b013e318219c171","volume":"128","author":"PB Burns","year":"2011","unstructured":"Burns PB, Rohrich RJ, Chung KC (2011) The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg 128(1):305\u2013310","journal-title":"Plast Reconstr Surg"},{"key":"5738_CR24","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"key":"5738_CR25","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919","journal-title":"BMJ"},{"issue":"10","key":"5738_CR26","first-page":"2127","volume":"18","author":"Z Munn","year":"2020","unstructured":"Munn Z, Barker TH, Moola S et al (2020) Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth 18(10):2127\u20132133","journal-title":"JBI Evid Synth"},{"issue":"22","key":"5738_CR27","doi-asserted-by":"publisher","first-page":"8540","DOI":"10.1002\/cam4.3449","volume":"9","author":"M Lin","year":"2020","unstructured":"Lin M, Jin Y, Jin J et al (2020) A risk stratification model for predicting brain metastasis and brain screening benefit in patients with metastatic triple-negative breast cancer. Cancer Med 9(22):8540\u20138551","journal-title":"Cancer Med"},{"issue":"6","key":"5738_CR28","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.clon.2020.02.007","volume":"32","author":"TG Wilson","year":"2020","unstructured":"Wilson TG, Robinson T, MacFarlane C et al (2020) Treating Brain Metastases from Breast Cancer: Outcomes after Stereotactic Radiosurgery. Clin Oncol (R Coll Radiol) 32(6):390\u2013396","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"9","key":"5738_CR29","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1007\/s12094-021-02577-x","volume":"23","author":"C Fabregat-Franco","year":"2021","unstructured":"Fabregat-Franco C, Stradella A, Navarro V et al (2021) Validation and comparison of Breast Graded Prognostic Assessment scores in patients with breast cancer and brain metastases. Clin Transl Oncol 23(9):1761\u20131768","journal-title":"Clin Transl Oncol"},{"issue":"18","key":"5738_CR30","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.1002\/cncr.25391","volume":"116","author":"A Niwi\u0144ska","year":"2010","unstructured":"Niwi\u0144ska A, Murawska M, Pogoda K (2010) Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases. Cancer 116(18):4238\u20134247","journal-title":"Cancer"},{"issue":"3","key":"5738_CR31","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s11060-011-0616-3","volume":"105","author":"A Niwi\u0144ska","year":"2011","unstructured":"Niwi\u0144ska A, Olszewski W, Murawska M et al (2011) Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes. J Neurooncol 105(3):547\u2013553","journal-title":"J Neurooncol"},{"issue":"16","key":"5738_CR32","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM et al (2021) Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med 384(16):1529\u20131541","journal-title":"N Engl J Med"},{"key":"5738_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2018.07.004","volume":"102","author":"I Witzel","year":"2018","unstructured":"Witzel I, Laakmann E, Weide R et al (2018) Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry. Eur J Cancer 102:1\u20139","journal-title":"Eur J Cancer"},{"issue":"19","key":"5738_CR34","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.1002\/cncr.27434","volume":"118","author":"S Dawood","year":"2012","unstructured":"Dawood S, Lei X, Litton JK et al (2012) Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. Cancer 118(19):4652\u20134659","journal-title":"Cancer"},{"issue":"3","key":"5738_CR35","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00259-014-2941-1","volume":"42","author":"D Groheux","year":"2015","unstructured":"Groheux D, Giacchetti S, Delord M et al (2015) Prognostic impact of 18F-FDG PET\/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer. Eur J Nucl Med Mol Imaging 42(3):377\u2013385","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"5738_CR36","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1007\/s12282-024-01565-7","volume":"31","author":"A De Moura","year":"2024","unstructured":"De Moura A, Loirat D, Vaillant S et al (2024) Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases. Breast Cancer 31(4):572\u2013580","journal-title":"Breast Cancer"},{"key":"5738_CR37","doi-asserted-by":"crossref","unstructured":"An R, Wang Y, Wang F et al Upfront stereotactic radiosurgery for brain metastases from triple-negative breast cancer. J Clin Oncol. 2021\/05\/20;39(15_suppl):e14014\u2013e14014","DOI":"10.1200\/JCO.2021.39.15_suppl.e14014"},{"issue":"2","key":"5738_CR38","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s11060-018-2805-9","volume":"138","author":"A Darlix","year":"2018","unstructured":"Darlix A, Griguolo G, Thezenas S et al (2018) Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer. J Neurooncol 138(2):369\u2013382","journal-title":"J Neurooncol"},{"issue":"1","key":"5738_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5603\/RPOR.a2021.0001","volume":"26","author":"I Ratosa","year":"2021","unstructured":"Ratosa I, Vidmar MS (2021) Stereotactic radiosurgery for patients with breast cancer brain oligometastases - molecular subtypes and clinical outcomes. Rep Pract Oncol Radiother 26(1):1\u201311","journal-title":"Rep Pract Oncol Radiother"},{"issue":"6","key":"5738_CR40","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.3171\/2022.10.JNS221900","volume":"138","author":"RO Kowalchuk","year":"2023","unstructured":"Kowalchuk RO, Niranjan A, Hess J et al (2023) Stereotactic radiosurgery and local control of brain metastases from triple-negative breast cancer. J Neurosurg 138(6):1608\u20131614","journal-title":"J Neurosurg"},{"key":"5738_CR41","doi-asserted-by":"publisher","first-page":"103757","DOI":"10.1016\/j.breast.2024.103757","volume":"76","author":"M Turna","year":"2024","unstructured":"Turna M, Y\u0131ld\u0131r\u0131m BA, Numanoglu \u00c7 et al (2024) Comprehensive analysis of stereotactic Radiosurgery outcomes in triple-negative breast cancer patients with brain metastases: The influence of immunotherapy and prognostic factors. Breast 76:103757","journal-title":"Breast"},{"issue":"3","key":"5738_CR42","first-page":"341","volume":"26","author":"W Haque","year":"2021","unstructured":"Haque W, Verma V, Adeberg S et al (2021) Outcomes following stereotactic radiosurgery or whole brain radiation therapy by molecular subtype of metastatic breast cancer. Rep Pract Oncol Radiother 26(3):341\u2013351","journal-title":"Rep Pract Oncol Radiother"},{"key":"5738_CR43","doi-asserted-by":"crossref","unstructured":"Bergen ES, Berghoff AS, Steindl A et al Androgen Receptor is Expressed in Breast Cancer Brain Metastases. Appl Immunohistochem Mol Morphol 2021 Nov-Dec 01;29(10):728\u2013733","DOI":"10.1097\/PAI.0000000000000952"},{"issue":"5","key":"5738_CR44","doi-asserted-by":"publisher","first-page":"102995","DOI":"10.1016\/j.esmoop.2024.102995","volume":"9","author":"D Dannehl","year":"2024","unstructured":"Dannehl D, Jakob D, Mergel F et al (2024) The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients-a multicenter real-world analysis. ESMO Open 9(5):102995","journal-title":"ESMO Open"},{"issue":"15suppl","key":"5738_CR45","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1200\/JCO.2021.39.15_suppl.1090","volume":"39","author":"JK Litton","year":"2021","unstructured":"Litton JK, Ettl J, Hurvitz SA et al (2021) Clinical outcomes in patients (pts) with a history of central nervous system (CNS) metastases receiving talazoparib (TALA) or physician\u2019s choice of chemotherapy (PCT) in the phase 3 EMBRACA trial. J Clin Oncol 39(15suppl):1090\u20131090","journal-title":"J Clin Oncol"},{"issue":"1","key":"5738_CR46","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","volume":"21","author":"P Schmid","year":"2020","unstructured":"Schmid P, Rugo HS, Adams S et al (2020) Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21(1):44\u201359","journal-title":"Lancet Oncol"},{"issue":"17","key":"5738_CR47","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1016\/j.ejca.2015.07.040","volume":"51","author":"VK Ho","year":"2015","unstructured":"Ho VK, Gijtenbeek JM, Brandsma D et al (2015) Survival of breast cancer patients with synchronous or metachronous central nervous system metastases. Eur J Cancer 51(17):2508\u20132516","journal-title":"Eur J Cancer"},{"issue":"3","key":"5738_CR48","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s10549-011-1682-0","volume":"129","author":"S Lee","year":"2011","unstructured":"Lee S, Ahn HK, Park YH et al (2011) Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations. Breast Cancer Res Treat 129(3):809\u2013817","journal-title":"Breast Cancer Res Treat"},{"issue":"31","key":"5738_CR49","doi-asserted-by":"publisher","first-page":"e21333","DOI":"10.1097\/MD.0000000000021333","volume":"99","author":"Y Okada","year":"2020","unstructured":"Okada Y, Abe T, Shinozaki M et al (2020) Evaluation of imaging findings and prognostic factors after whole-brain radiotherapy for carcinomatous meningitis from breast cancer: A retrospective analysis. Med (Baltim) 99(31):e21333","journal-title":"Med (Baltim)"},{"key":"5738_CR50","doi-asserted-by":"publisher","first-page":"8816102","DOI":"10.1155\/2024\/8816102","volume":"2024","author":"E Bustamante","year":"2024","unstructured":"Bustamante E, Casas F, Luque R et al (2024) Brain Metastasis in Triple-Negative Breast Cancer. Breast J 2024:8816102","journal-title":"Breast J"},{"key":"5738_CR51","doi-asserted-by":"crossref","unstructured":"Vogelbaum MA, Brown PD, Messersmith H et al Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol. 2021 2022\/02\/10;40(5):492\u2013516","DOI":"10.1200\/JCO.21.02314"},{"key":"5738_CR52","doi-asserted-by":"crossref","unstructured":"Gondi V, Bauman G, Bradfield L et al (2022 Jul-Aug) Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol 12(4):265\u2013282","DOI":"10.1016\/j.prro.2022.02.003"},{"issue":"11","key":"5738_CR53","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","volume":"32","author":"E Le Rhun","year":"2021","unstructured":"Le Rhun E, Guckenberger M, Smits M et al (2021) EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann Oncol 32(11):1332\u20131347","journal-title":"Ann Oncol"},{"issue":"3","key":"5738_CR54","doi-asserted-by":"publisher","first-page":"E201","DOI":"10.1093\/neuros\/nyy547","volume":"84","author":"JB Elder","year":"2019","unstructured":"Elder JB, Nahed BV, Linskey ME et al (2019) Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Emerging and Investigational Therapties for the Treatment of Adults With Metastatic Brain Tumors. Neurosurgery 84(3):E201\u2013e203","journal-title":"Neurosurgery"},{"issue":"5","key":"5738_CR55","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","volume":"22","author":"WJ Gradishar","year":"2024","unstructured":"Gradishar WJ, Moran MS, Abraham J et al (2024) Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 22(5):331\u2013357","journal-title":"J Natl Compr Canc Netw"},{"issue":"Suppl 4","key":"5738_CR56","doi-asserted-by":"publisher","first-page":"S192","DOI":"10.4103\/2152-7806.111296","volume":"4","author":"KJ Stelzer","year":"2013","unstructured":"Stelzer KJ (2013) Epidemiology and prognosis of brain metastases. Surg Neurol Int 4(Suppl 4):S192\u2013202","journal-title":"Surg Neurol Int"},{"issue":"10","key":"5738_CR57","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1093\/neuonc\/noac118","volume":"24","author":"AA Aizer","year":"2022","unstructured":"Aizer AA, Lamba N, Ahluwalia MS et al (2022) Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. Neuro Oncol 24(10):1613\u20131646","journal-title":"Neuro Oncol"},{"issue":"21","key":"5738_CR58","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","volume":"295","author":"H Aoyama","year":"2006","unstructured":"Aoyama H, Shirato H, Tago M et al (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295(21):2483\u20132491","journal-title":"JAMA"},{"issue":"2","key":"5738_CR59","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","volume":"29","author":"M Kocher","year":"2011","unstructured":"Kocher M, Soffietti R, Abacioglu U et al (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952\u201326001 study. J Clin Oncol 29(2):134\u2013141","journal-title":"J Clin Oncol"},{"issue":"4","key":"5738_CR60","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jama.2016.9839","volume":"316","author":"PD Brown","year":"2016","unstructured":"Brown PD, Jaeckle K, Ballman KV et al (2016) Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA 316(4):401\u2013409","journal-title":"JAMA"},{"issue":"8","key":"5738_CR61","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","volume":"18","author":"PD Brown","year":"2017","unstructured":"Brown PD, Ballman KV, Cerhan JH et al (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18(8):1049\u20131060","journal-title":"Lancet Oncol"},{"issue":"10","key":"5738_CR62","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1093\/neuonc\/not114","volume":"15","author":"PD Brown","year":"2013","unstructured":"Brown PD, Pugh S, Laack NN et al (2013) Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol 15(10):1429\u20131437","journal-title":"Neuro Oncol"},{"issue":"10","key":"5738_CR63","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1200\/JCO.19.02767","volume":"38","author":"PD Brown","year":"2020","unstructured":"Brown PD, Gondi V, Pugh S et al (2020) Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. J Clin Oncol 38(10):1019\u20131029","journal-title":"J Clin Oncol"},{"issue":"1","key":"5738_CR64","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41523-024-00635-5","volume":"10","author":"SA Hurvitz","year":"2024","unstructured":"Hurvitz SA, Bardia A, Punie K et al (2024) Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer 10(1):33","journal-title":"NPJ Breast Cancer"},{"issue":"11","key":"5738_CR65","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","volume":"31","author":"JK Litton","year":"2020","unstructured":"Litton JK, Hurvitz SA, Mina LA et al (2020) Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol 31(11):1526\u20131535","journal-title":"Ann Oncol"},{"issue":"8","key":"5738_CR66","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","volume":"32","author":"LA Emens","year":"2021","unstructured":"Emens LA, Adams S, Barrios CH et al (2021) First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol 32(8):983\u2013993","journal-title":"Ann Oncol"},{"issue":"5","key":"5738_CR67","first-page":"331","volume":"29","author":"AB Sharabi","year":"2015","unstructured":"Sharabi AB, Tran PT, Lim M et al (2015) Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. Oncol (Williston Park) 29(5):331\u2013340","journal-title":"Oncol (Williston Park)"},{"issue":"9","key":"5738_CR68","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1093\/annonc\/mdn283","volume":"19","author":"SL Hines","year":"2008","unstructured":"Hines SL, Vallow LA, Tan WW et al (2008) Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and\/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann Oncol 19(9):1561\u20131565","journal-title":"Ann Oncol"},{"issue":"1","key":"5738_CR69","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10549-019-05445-z","volume":"179","author":"JP Leone","year":"2020","unstructured":"Leone JP, Duda DG, Hu J et al (2020) A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. Breast Cancer Res Treat 179(1):113\u2013123","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"5738_CR70","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10549-020-05727-x","volume":"182","author":"AK Tzikas","year":"2020","unstructured":"Tzikas AK, Nemes S, Linderholm BK (2020) A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns. Breast Cancer Res Treat 182(3):643\u2013654","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"5738_CR71","doi-asserted-by":"publisher","first-page":"7951","DOI":"10.1002\/cam4.5575","volume":"12","author":"Y Yang","year":"2023","unstructured":"Yang Y, Zhang L, Tian W et al (2023) Prognosis prediction and risk factors for triple-negative breast cancer patients with brain metastasis: A population-based study. Cancer Med 12(7):7951\u20137961","journal-title":"Cancer Med"},{"issue":"27","key":"5738_CR72","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1200\/JCO.2018.79.2713","volume":"36","author":"N Ramakrishna","year":"2018","unstructured":"Ramakrishna N, Temin S, Chandarlapaty S et al (2018) Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. J Clin Oncol 36(27):2804\u20132807","journal-title":"J Clin Oncol"},{"issue":"2","key":"5738_CR73","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2020.11.003","volume":"32","author":"P Roth","year":"2021","unstructured":"Roth P, Pace A, Le Rhun E et al (2021) Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. Ann Oncol 32(2):171\u2013182","journal-title":"Ann Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05738-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05738-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05738-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:02:30Z","timestamp":1788253350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05738-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5738"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05738-6","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"19 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is a systematic review of previously published literature and publicly available data. Therefore, ethical approval was not required.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"27"}}